 |
|
Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In Reply: We recognize that potential biases may exist because of possible differences in follow-up times or related chemotherapies between bevacizumab and control groups, as pointed out by Dr Minor and by Dr Cortes and colleagues. The prolonged time to progression frequently associated with bevacizumab therapy might result in more follow-up time or exposure to chemotherapy in bevacizumab groups, potentially leading to increased VTE. However, we analyzed 3 RCTs in which bevacizumab was not associated with significant progression-free survival1-3 and 1 trial in which follow-up time was not significantly different between the bevacizumab group (median, 13.3 months; range, 0-25.6 months) and controls (median, 12.8 months; range, 0-24.2 months).4 We found that the RR of VTE with bevacizumab from these 4 RCTs was 1.39 (95% confidence interval [CI], 0.97-2.01). In addition, the RR was 1.32 (95% CI, 1.10-1.59) from 10 RCTs in which the follow-up time was not specified for bevacizumab . . . [Full Text of this Article]
David Chu, MD;
Shenhong Wu, MD, PhD
shenhong.wu@stonybrook.edu
Division of Medical Oncology
Department of Medicine
Stony Brook University
Stony Brook, New York
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTERS
Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
David R. Minor
JAMA. 2009;301(14):1434.
EXTRACT
| FULL TEXT
Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
Javier Cortes, Cristina Saura, and Francesco Atzori
JAMA. 2009;301(14):1434-1435.
EXTRACT
| FULL TEXT
Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients
Saadettin Kilickap and Cagatay Arslan
JAMA. 2009;301(14):1435.
EXTRACT
| FULL TEXT
|
